REDWOOD CITY, Calif.
Feb. 21, 2012
/PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that
, President and Chief Executive Officer, will present at two separate investor conferences, one in
New York City
, NY and one in
, over the coming weeks as follows:
Citi 2012 Global Health Care Conference
Tuesday, February 28th
10:30 AM EST
Location: Waldorf Astoria Hotel in
New York, NY
Cowen and Company 32nd Annual Health Care Conference
Tuesday, March 6th
9:20 AM EST
Location: The Boston Marriott Copley Place in
Both presentations will be webcast live and can be accessed through the links above. For those not available to listen to the live broadcast, the presentations will be archived and available through
About AcelRx Pharmaceuticals, Inc.
Redwood City, CA
, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the first quarter of 2012 under a grant from the US Army Medical Research and Material Command, or USAMRMC.